Key Points
Question Does prolonged and exclusive breastfeeding reduce the risk of asthma and atopic eczema and improve lung function in adolescence?
SHORT REPORT
OPEN ACCESS
November 18, 2017
November 16, 2017
November 13, 2017
Adherence with epinephrine autoinjector prescriptions in primary care
Abstract
Background
The aim of this study was to estimate primary adherence for epinephrine autoinjector (EA) prescriptions in primary care practices in Manitoba, Canada.
November 6, 2017
Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study
BMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j4619 (Published 26 October 2017)
Cite this as: BMJ 2017;359:j4619- Jessica J Liu, internist and assistant professor1 2,
- Chaim M Bell, internist and professor1 2 3 4,
- John J Matelski, biostatistician2,
- Allan S Detsky, internist and professor1 2 3,
- Peter Cram, internist and professor1 2 3 4
- Correspondence to: J J Liu Department of Medicine, Division of General Internal Medicine, University Health Network and Sinai Health System, Toronto, Ontario, Canada jessica.liu@uhn.ca
EAACI Guidelines on Allergen Immunotherapy (AIT)
EAACI has a long history and strong ethos in implementing the latest research findings to deliver better healthcare for patients with allergies. Over the last decades this mission has become even more important with allergic diseases now affecting the lives of millions of people around the world. This represents a major burden for patients as well as their clinicians, governments, legislators and regulators. The current challenge is to deliver appropriate treatments that are able to prevent lifetime disabilities, shifting from “treating a disease“ to “promote health” in a sustainable context.
Allergen immunotherapy (AIT) has been used for a century. Several terms including “desensitization”, “hyposensitization“ and “vaccines” have been used, and often misused, to indicate administration of incremental doses of allergenic substances to reduce the clinical manifestations of allergy. However AIT has also been the subject of considerable controversy in terms of its efficacy. The dispute has impacted on the dissemination of knowledge about AIT, the availability of the products in many countries and the relevant policies for their reimbursement. Some of these issues result from an inadequate translation of the scientific data into daily practice, with clinical judgment being established on expert opinion instead of the objective evaluation of valid scientific studies.
Article InfoOctober 21, 2017
Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology
POSITION PAPER
P. W. Hellings, L. Klimek, C. Cingi, I. Agache, C. Akdis, C. Bachert, J. Bousquet, P. Demoly, P. Gevaert, V. Hox, C. Hupin, L. Kalogjera, F. Manole, R. Mösges, J. Mullol, N. B. Muluk, A. Muraro, N. Papadopoulos, R. Pawankar, C. Rondon, M. Rundenko, S. F. Seys, E. Toskala, L. Van Gerven, L. Zhang, N. Zhang, W. J. Fokkens
Abstract
This EAACI position paper aims at providing a state-of-the-art overview on nonallergic rhinitis (NAR). A significant number of patients suffering from persistent rhinitis are defined as nonallergic noninfectious rhinitis (NANIR) patients, often denominated in short as having NAR. NAR is defined as a symptomatic inflammation of the nasal mucosa with the presence of a minimum of two nasal symptoms such as nasal obstruction, rhinorrhea, sneezing, and/or itchy nose, without clinical evidence of endonasal infection and without systemic signs of sensitization to inhalant allergens.
Subscribe to:
Posts (Atom)